DNL343 was developed to target eIF2B, a central regulator of the integrated stress response (ISR), which is overactive in ALS. This overactivity leads to formation of stress granules containing ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.